Alzinova’s promising Phase 1b results have attracted attention and received positive recognition from both stakeholders and industry peers. To maximize impact, the company has chosen to focus on preparing the results for publication in a peer-reviewed scientific journal, an approach that enhances credibility and ensures broad international reach. Instead of presenting the data at AAIC, this strategic step is now being prioritized with the aim of submitting the manuscript during the third quarter of 2025.

Simultaneously, Alzinova continues to advance its partnership discussions as well as the regulatory and operational preparations for the Phase II study, which is expected to commence in the second half of 2025. The company will provide timely updates to the market as material developments arise, ensuring that shareholders and the market remain well informed.

For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com

About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com